What's Going On With Moderna Stock Today?

Moderna Inc MRNA announced changes to its operating model to bring focus to its short- and long-term business goals.

The company is focused on driving continued sales of its COVID-19 vaccine and launching its Respiratory syncytial virus (RSV) vaccine in 2024, while also preparing to launch multiple products per year from 2025 forward. 

The company has decided to increase executive focus on driving sales of Spikevax and the expected launch of its RSV vaccine next year. 

Last month, the European Patent Office said a contested mRNA patent owned by Moderna is invalid, marking a victory for Pfizer Inc PFE/BioNTech SE BNTX in a patent dispute between the biggest coronavirus vaccine makers. 

To do this, Stephane Bancel, Chief Executive Officer of Moderna, will assume responsibility for sales and marketing in 2024, working directly with the commercial team. 

To ensure the company maintains momentum on its launches beyond 2024, Stephen Hoge, President of Moderna, will assume responsibility for pipeline commercial strategy and Medical Affairs. 

As part of these changes, Arpa Garay, previously Chief Commercial Officer, is expected to leave the company in the coming months and will remain an advisor during the transition.

Monday, Merck & Co Inc MRK and Moderna initiated an INTerpath-002 Phase 3 randomized trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with Keytruda, as adjuvant treatment in patients with completely resected Stage II, IIIA or IIIB non-small cell lung cancer.

Global recruitment of the INTerpath-002 has begun, and the first patients enrolled in Australia.

Price Action: MRNA shares are down 5.54% at $77.47 on the last check Tuesday.